207 related articles for article (PubMed ID: 26433463)
1. Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors.
Colbeck EJ; Hindley JP; Smart K; Jones E; Bloom A; Bridgeman H; McPherson RC; Turner DG; Ladell K; Price DA; O'Connor RA; Anderton SM; Godkin AJ; Gallimore AM
Oncotarget; 2015 Sep; 6(28):24649-59. PubMed ID: 26433463
[TBL] [Abstract][Full Text] [Related]
2. T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2.
Koch MA; Thomas KR; Perdue NR; Smigiel KS; Srivastava S; Campbell DJ
Immunity; 2012 Sep; 37(3):501-10. PubMed ID: 22960221
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.
Hindley JP; Ferreira C; Jones E; Lauder SN; Ladell K; Wynn KK; Betts GJ; Singh Y; Price DA; Godkin AJ; Dyson J; Gallimore A
Cancer Res; 2011 Feb; 71(3):736-46. PubMed ID: 21156649
[TBL] [Abstract][Full Text] [Related]
4. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity.
Redjimi N; Raffin C; Raimbaud I; Pignon P; Matsuzaki J; Odunsi K; Valmori D; Ayyoub M
Cancer Res; 2012 Sep; 72(17):4351-60. PubMed ID: 22798340
[TBL] [Abstract][Full Text] [Related]
5. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
6. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ
J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563
[TBL] [Abstract][Full Text] [Related]
7. IL-2/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4
Yan JJ; Lee JG; Jang JY; Koo TY; Ahn C; Yang J
Kidney Int; 2017 Mar; 91(3):603-615. PubMed ID: 27914701
[TBL] [Abstract][Full Text] [Related]
8. RORγt Promotes Foxp3 Expression by Antagonizing the Effector Program in Colonic Regulatory T Cells.
Bhaumik S; Mickael ME; Moran M; Spell M; Basu R
J Immunol; 2021 Oct; 207(8):2027-2038. PubMed ID: 34518282
[TBL] [Abstract][Full Text] [Related]
9. MondoA-Thioredoxin-Interacting Protein Axis Maintains Regulatory T-Cell Identity and Function in Colorectal Cancer Microenvironment.
Lu Y; Li Y; Liu Q; Tian N; Du P; Zhu F; Han Y; Liu X; Liu X; Peng X; Wang X; Wu Y; Tong L; Li Y; Zhu Y; Wu L; Zhang P; Xu Y; Chen H; Li B; Tong X
Gastroenterology; 2021 Aug; 161(2):575-591.e16. PubMed ID: 33901495
[TBL] [Abstract][Full Text] [Related]
10. The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells.
MaruYama T; Kobayashi S; Nakatsukasa H; Moritoki Y; Taguchi D; Sunagawa Y; Morimoto T; Asao A; Jin W; Owada Y; Ishii N; Iwabuchi Y; Yoshimura A; Chen W; Shibata H
Front Immunol; 2021; 12():687669. PubMed ID: 34248973
[TBL] [Abstract][Full Text] [Related]
11. [Proliferation of CD4+ CD25+ regulatory T cells of rat by different cytokines in vitro].
Wang ZH; Zhu JY; Li T; Leng XS
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):844-7. PubMed ID: 18756991
[TBL] [Abstract][Full Text] [Related]
12. ICOS
Nagase H; Takeoka T; Urakawa S; Morimoto-Okazawa A; Kawashima A; Iwahori K; Takiguchi S; Nishikawa H; Sato E; Sakaguchi S; Mori M; Doki Y; Wada H
Int J Cancer; 2017 Feb; 140(3):686-695. PubMed ID: 27756099
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins.
Bui JD; Uppaluri R; Hsieh CS; Schreiber RD
Cancer Res; 2006 Jul; 66(14):7301-9. PubMed ID: 16849580
[TBL] [Abstract][Full Text] [Related]
14.
Berretta F; Piccirillo CA; Stevenson MM
Front Immunol; 2019; 10():425. PubMed ID: 30915078
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-γ, IL-2 and IL-2R.
Zhao J; Zhao J; Perlman S
PLoS One; 2012; 7(9):e46241. PubMed ID: 23029447
[TBL] [Abstract][Full Text] [Related]
16. IL-2-deprivation and TGF-beta are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25- cell activation.
Wang G; Khattar M; Guo Z; Miyahara Y; Linkes SP; Sun Z; He X; Stepkowski SM; Chen W
Immunol Lett; 2010 Aug; 132(1-2):61-8. PubMed ID: 20570629
[TBL] [Abstract][Full Text] [Related]
17. Pathogen-specific Treg cells expand early during mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12.
Shafiani S; Dinh C; Ertelt JM; Moguche AO; Siddiqui I; Smigiel KS; Sharma P; Campbell DJ; Way SS; Urdahl KB
Immunity; 2013 Jun; 38(6):1261-70. PubMed ID: 23791647
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL-2 treatment impairs the expansion of T(reg) cell population during acute malaria and enhances the Th1 cell response at the chronic disease.
Zago CA; Bortoluci KR; Sardinha LR; Pretel FD; Castillo-Méndez SI; Freitas do Rosário AP; Hiyane MI; Muxel SM; Rodriguez-Málaga SM; Abrahamsohn IA; Álvarez JM; D'Império Lima MR
PLoS One; 2012; 7(1):e29894. PubMed ID: 22272258
[TBL] [Abstract][Full Text] [Related]
19. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E
Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008
[TBL] [Abstract][Full Text] [Related]
20. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
